Any current/future new fundraising through debt or equity?

In the FY26 earnings call, there was no explicit mention of any new fundraising plans through debt or equity. The company reported a comfortable leverage position with net debt at INR33.6 crores and a net debt-to-equity ratio of 0.04x as of March 31, 2026. Capex for FY27 is expected to be moderate, with major greenfield expansions largely completed and maintenance capex around INR15 crores. The battery materials project’s upcoming expansion (up to 100,000 metric tons capacity) involves a total capex estimate of around INR600 crores, but no specific fundraising plans were disclosed. Overall, th

Any current/future capex/capital investment/strategic investment?

**Battery Materials Project at Dahej**: Phase 1 capacity of 25,000 metric tons yearly, commissioning by April 2027. Total target capacity up to 100,000 metric tons with approx. INR 600 crores capex planned. **Greenfield Manufacturing Project**: Focused on pharma, food, and nutrition verticals, enhancing capabilities for high-value mineral molecules like glycinate and gluconate. Internal production validation completed; customer qualification ongoing. **Capex in FY26**: INR 127 crores (including INR 34 crores for SAM land, INR 80 crores Greenfield project, INR 13 crores maintenance). **Ca

Future growth expectations in sales/revenue/volumes?

Pharma Food Nutrition (PFN) segment expected to grow faster than the 10% achieved in FY26 in both FY27 and FY28. Specialty Ingredients segment forecasted to continue similar growth as in the past 2-3 years, maintaining strong momentum. Bisglycinate product category projected to become a sizable revenue contributor starting FY28. With the greenfield facility operational, pharma food nutrition volumes have grown over 20%, expecting further growth with capacity expansion. Battery materials volume is expected to scale up, with a fair assumption of selling around 2,500 metric tons in FY27. Overall,

Future growth expectations in earnings/operating earnings/profits/EPS?

FY27 is expected to mark an important inflection point with continued momentum in both pharma food nutrition and specialty ingredients verticals. Pharma food nutrition segment is expected to grow faster than the 10% growth seen in FY26. Specialty ingredients vertical to maintain similar growth rates seen in the last 2-3 years. Margins to recover to historical levels around 37-38% EBITDA by FY27 after current upfront investments. Excluding battery materials, business can scale to INR 1000-1200 crores revenue without incremental capex. Battery materials segment (at full 100,000 tons capacity) co

Current/ Expected Orderbook/ Pending Orders?

Sudeep Pharma has a strong order book with ongoing commercial purchase orders, including approximately 700 metric tons for battery materials received recently. The company is engaged with 42 global customers across the cathode, cell, EV, and ESS ecosystem; 22 at lab validation, 14 at pilot scale, and 6 at commercial validation. For battery materials, customer engagement and qualification progress are encouraging, with active off-take discussions. Specialty ingredients segment has good visibility with approvals from large global customers in encapsulation technology and infant nutrition premix

IN US

Sale is live|00:00:00left today

Sudeep Pharma LtdQ1 FY26Pharmaceuticals & Biotechnology

Sudeep Pharma Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹809P/E: 46.5Market Cap: ₹7.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Pharma Food Nutrition (PFN) segment expected to grow faster than the 10% achieved in FY26 in both FY27 and FY28.
→Specialty Ingredients segment forecasted to continue similar growth as in the past 2-3 years, maintaining strong momentum.
→Bisglycinate product category projected to become a sizable revenue contributor starting FY28.
→With the greenfield facility operational, pharma food nutrition volumes have grown over 20%, expecting further growth with capacity expansion.
→Battery materials volume is expected to scale up, with a fair assumption of selling around 2,500 metric tons in FY27.
→Overall, the company confident about sustaining momentum in FY27 with focus on higher-value products and deeper global customer engagement.
→Excluding battery materials, business can scale up to approximately INR 1000-1200 crores revenue without additional capex.

Margin guidance

Category 3

→FY27 is expected to mark an important inflection point with continued momentum in both pharma food nutrition and specialty ingredients verticals.
→Pharma food nutrition segment is expected to grow faster than the 10% growth seen in FY26.
→Specialty ingredients vertical to maintain similar growth rates seen in the last 2-3 years.
→Margins to recover to historical levels around 37-38% EBITDA by FY27 after current upfront investments.
→Excluding battery materials, business can scale to INR 1000-1200 crores revenue without incremental capex.
→Battery materials segment (at full 100,000 tons capacity) could generate INR 1600-1800 crores revenue.
→Overall margins expected to return to historical averages (24-25% PAT margin) once investments and new teams start contributing positively.
→Focus remains on margin expansion through higher-value product mix and efficient operations over time.

3 more insights locked — sign up free to unlock

Fundraise plans

→In the FY26 earnings call, there was no explicit mention of any new fundraising plans through debt or equity.
→The company reported a comfortable leverage position with net debt at INR33.6 crores and a net debt-to-equity ratio of 0.04x as of March 31, 2026.
→Capex for FY27 is expected to be moderate, with major greenfield expansions largely completed and maintenance capex around INR15 crores.
→The battery materials project’s upcoming expansion (up to 100,000 metric tons capacity) involves a total capex estimate of around INR600 crores, but no specific fundraising plans were disclosed.
→Overall, the management focused on operational growth and margin improvement without indicating immediate plans for raising funds through debt or equity.

Order book

Yes

→Sudeep Pharma has a strong order book with ongoing commercial purchase orders, including approximately 700 metric tons for battery materials received recently.
→The company is engaged with 42 global customers across the cathode, cell, EV, and ESS ecosystem; 22 at lab validation, 14 at pilot scale, and 6 at commercial validation.
→For battery materials, customer engagement and qualification progress are encouraging, with active off-take discussions.
→Specialty ingredients segment has good visibility with approvals from large global customers in encapsulation technology and infant nutrition premix categories.
→The company expects the specialty ingredients segment to maintain its growth momentum in FY27.
→For FY27, a commercial sale of around 2,500 metric tons of battery-grade iron phosphate is a fair volume assumption.
→Overall, momentum across both verticals (pharma food nutrition and specialty ingredients) is expected to continue growing in FY27 and FY28.

Capex plans

Yes

→**Battery Materials Project at Dahej**: Phase 1 capacity of 25,000 metric tons yearly, commissioning by April 2027. Total target capacity up to 100,000 metric tons with approx. INR 600 crores capex planned.
→**Greenfield Manufacturing Project**: Focused on pharma, food, and nutrition verticals, enhancing capabilities for high-value mineral molecules like glycinate and gluconate. Internal production validation completed; customer qualification ongoing.
→**Capex in FY26**: INR 127 crores (including INR 34 crores for SAM land, INR 80 crores Greenfield project, INR 13 crores maintenance).
→**Capex in FY27**: Expected around INR 10 crores to complete Greenfield project, plus maintenance capex of INR 15 crores in core business; additional capex for battery materials projects continues.
→**Strategic investments**: Expansion of commercial presence, technical teams, inventory, and warehousing in North America and Europe for Specialty Ingredients and Pharma Food Nutrition verticals.

How does Sudeep Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Sudeep Pharma Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Sudeep Pharma Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio